Objective: Status epilepticus (SE) is a life-threatening and commonly drug-refractory condition. Novel therapies are needed to rapidly terminate seizures to prevent mortality and morbidity. Monoacylglycerol lipase (MAGL) is the key enzyme responsible for the hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG) and a major contributor to the brain pool of arachidonic acid (AA). Inhibiting of monoacylglycerol lipase modulates synaptic activity and neuroinflammation, 2 mediators of excessive neuronal activation underlying seizures. We studied the effect of a potent and selective irreversible MAGL inhibitor, CPD-4645, on SE that was refractory to diazepam, its neuropathologic sequelae, and the mechanism underlying the drug's effects. Methods: Diazepam-resistant SE was induced in adult mice fed with standard or ketogenic diet or in cannabinoid receptor type 1 (CB1) receptor knock-out mice.
| INTRODUCTION
Status epilepticus (SE) is a common life-threatening condition with a prevalence of 10-41/100 000 people. 1 Approximately 50% of these cases present with no prior diagnosis of epilepsy. 1 About 20% of patients die as a result of SE. 1 Current standard of care includes treatment with first-or second-line agents (benzodiazepines and standard antiepileptic drugs [AEDs]), followed by additional benzodiazepines and other agents such as barbiturates and propofol to eliminate unremitting seizures as quickly as possible. 1,2 About one-third of patients still continue seizing despite the treatment, thus evolving to refractory SE, and half of these subsequently develop superrefractory SE, resistant to anesthetic treatment. 1 Furthermore, refractory SE is linked to a worse prognosis, both in terms of mortality and morbidity. Decline in intellectual function and cognitive deficits have been reported, particularly in new-onset refractory SE in both children and adults. 3, 4 Moreover, chronic epilepsy occurs in up to 50% of adults after de novo refractory SE. 4 In rodent models, SE is typically induced by injecting a chemoconvulsant or by electrical stimulation of seizure-prone brain areas, thus mirroring some characteristics of de novo SE in humans. 5, 6 In particular, experimental studies in multiple mammalian species have demonstrated that SE itself is sufficient to induce cell damage, neurologic comorbidities, and the development of epilepsy, 5 thereby supporting that the occurrence of prolonged unremitting seizures may contribute to pathologic outcomes in humans in addition to underlying pathologies. 7, 8 The correlation between SE in preclinical models and humans provides an ideal platform for developing new treatments that can move from laboratory testing to a clinical population with high unmet need. The search for potential therapeutic targets led to the identification of molecular mechanisms underlying SE development in rodents. Both the endocannabinoid system and the proinflammatory arachidonic acid (AA)-derived eicosanoid cascade appear to play a significant role in experimental seizures in animals, as well as in downstream events including cell loss and comorbidities. 9, 10 These 2 pathways are functionally linked in the brain by the activity of the serine hydrolase monoacylglycerol lipase (MAGL), a constitutive enzyme that hydrolyzes the endocannabinoid 2-arachidoylglycerol (2-AG) to provide a major AA pool for proinflammatory eicosanoid synthesis. 11, 12 Thus MAGL -expressed mainly in the hippocampus, striatum, cerebellum, and frontal cortex-represents a critical node for regulating these lipid-signaling pathways in brain in physiopathologic conditions. 13 Moreover, recent evidence has suggested a potential role for MAGL in regulating neuronal hyperexcitability that is underlying seizures. 14, 15 Based on this premise, we investigated if MAGL inhibition, using the brain penetrant and selective inhibitor CPD-4645, affects diazepam-resistant SE in mice and reduces pathologic sequelae such as cognitive deficits and neuronal cell loss. To further characterize the mechanism of action, we investigated whether CPD-4645 effects were mediated by a reduction of excitatory synaptic transmission due to 2-AG modulation of cannabinoid receptor type 1 (CB1) receptors 16 or by antiinflammatory effects due to reduction of AA availability for the eicosanoid cascade and 2-AG activation of microglial cannabinoid receptor type 2 (CB2) receptors. 12, 16 Finally, we studied the effect of MAGL inhibition on SE in mice fed with a ketogenic diet (KD) for assessing a potential synergy between these 2 treatments since the KD is one therapeutic option for controlling refractory SE in humans. 17, 18 Moreover, the KD induces antiinflammatory effects, by reducing AA availability and modulating brain and blood levels of interleukin 1b (IL-1b), as part of its broad mechanism of action. 
| Induction of status epilepticus
Mice were surgically implanted under general gas anesthesia (1-3% isoflurane in O 2 ) and stereotaxic guidance. A 23-gauge guide cannula was unilaterally positioned on top of the dura mater for the intraamygdalar injection of kainic acid (KA) (from bregma, mm: nose bar 0; anteroposterior, À1.06; lateral, À2.75). 22 In mice a nichromeinsulated bipolar depth electrode (60 lm (outside diameter [OD])) was implanted in the dorsal hippocampus (from bregma, mm: nose bar 0; anteroposterior À1.8, lateral 1.5 and 2.0 below dura mater) 22 ipsilateral to the injected amygdala, and a cortical electrode was placed onto the somatosensory cortex in the contralateral hemisphere. EEG activity was recorded using the Twin EEG Recording System (version 4.5.3.23; Grass-Telefactor, West Warwick, RI, USA) connected with a Comet AS-40 32/8 Amplifier (sampling rate 400 Hz, high-pass filter 0.3 Hz, low-pass filter 70 Hz; a notch 50 Hz filter was also applied to remove artifact depending on local power system frequency. Digitized electroencephalography (EEG) data were processed using the Twin record and review software. Before the KA injection, EEG baseline was recorded in each mouse for 1 h. Kainic acid (0.3 lg in 0.2 lL) was injected into the basolateral amygdala in freely moving mice (n = 70) using a needle protruding 3.9 mm below the implanted cannula. As described previously, 23 SE developed after approximately 10 min from KA injection, and was defined by the appearance of continuous spikes with a frequency >1.0 Hz. Spikes were defined as sharp waves with an amplitude at least 2.5-fold higher than the standard deviation of the baseline EEG signal ( Figure S2 ) and a duration of <20 msec, or as a spike-and-wave with a duration of <200 m. SE was successfully evoked in 65 of 70 mice, of which 10 mice died; therefore 55 mice were used for the experiments. The total number of spikes was measured during 12 h after KA administration (Clampfit 9.0; Axon Instruments, Union City, CA, USA).
The effect of CPD-4645 versus its vehicle was tested in 32 mice fed with a standard diet (SD; 2018S; Envigo, Udine, Italy) and 23 mice fed for 4 weeks with a ketogenic diet (KD; #F3666; Bio-serv, Frenchtown, NJ, USA).
At the end of SE, mouse behavior was tested in a recognition memory task (novel object recognition test); then the animal's brain was used for histologic analysis of cell loss in the hippocampus and amygdala (see below). Two additional SHAM (not exposed to SE) groups underwent the same surgical procedures and were fed either SD (n = 12) or KD (n = 7). These mice were used as controls in the novel object recognition test and for histologic analysis.
| CPD-4645 treatment
Mice were fed ad libitum with SD or KD for 4 weeks to induce ketosis (Appendix S1). Mice in each diet group received intraamygdalar KA (as above), and 1 h after SE onset, animals were randomized to either CPD-4645 (10 mg/kg, subcutaneously [sc] , dissolved in DMSO-toCremophor-to-saline [ratio 0.5% dimethyl sulfoxide (DMSO) to 0.5% Cremophor]) or vehicle injection. A second injection of either drug or vehicle was done in the same mice 7 h post-SE onset (ie, 6 h after the first TERRONE ET AL.
| 81 injection) to maintain therapeutic drug levels as indicated by pharmacokinetic and pharmacodynamic analyses (Fig.  S1 ), followed by twice a day treatment for the following week until completion of behavioral test. The second injection of drug ensured >90% MAGL inhibition during the critical time window of SE development. Although the inhibition is irreversible, 90% MAGL inhibition is required to trigger significant increase in 2-AG (>29) and decrease in AA (at least 50%). The kinetics of this pharmacodynamic response requiring >90% MAGL inhibition is governed by MAGL resynthesis rate (11 h for 50% reconstitution in the mouse) and the compound clearance (4 h half-life in the mouse).
| Cnr1
À/À (n = 18) and their WT littermate control mice (n = 16) were fed ad libitum with SD. Mice underwent the same SE protocol as described earlier. SE was successfully evoked in 28 mice (3 mice in each strain were therefore excluded) that were randomized to either CPD-4645 (10 mg/kg, sc) or vehicle injection following the same treatment schedule described earlier.
| Novel object recognition test (NORT)
All experiments began between 9:00 and 10:00 AM. Two days after the end of SE, mice were tested in the NORT, a measure of recognition memory. 24 Although this task is associated with the perirhinal cortex function, we used a 24 h intertrial interval from familiarization to test phase, a condition that also involves hippocampal activity. 24 Twenty-four hours prior to the test, mice were allowed to habituate in the arena for 5 min. The test began on the next day with the familiarization phase, when mice were placed into the open field for 10 min in the presence of 2 identical objects positioned in internal nonadjacent squares. Cumulative exploration time (sniffing, touching, and stretching the head toward the object at a distance not >2 cm) of both objects and of each object separately was recorded. Twenty-four hours after familiarization, mice were placed for 10 min in the open field, which contained one object presented during the familiarization phase (familiar object, F), and a novel unfamiliar object (N). The time spent exploring N versus F represents a measure of trial unique recognition memory. Because the recognition phase was performed 24 h after the familiarization phase, the procedure can be regarded as a test of long-term memory. Time spent (s) exploring F and N was expressed as a discrimination index:
| Fluoro-Jade staining
At the end of the behavioral test, mice were deeply anesthetized (10% ketamine + 10% medetomidine + 80% saline; 10 mL/kg, ip), and then perfused via the ascending aorta with cold phosphate-buffered saline (PBS; 50 mmol L À1 , .18 AE 0.9, P < .01; n = 5 each group) pH 7.4). After decapitation, brains were processed for Fluoro-Jade (F-J) staining to detect degenerating neurons. 25 Four septal slices for each animal's brain (from bregma, À1.22 to À2.54 mm) 22 from control and experimental mice were matched for anteroposterior level. Briefly, images of the dorsal hippocampus and amygdala in the right hemisphere ipsilateral to the injected amygdala were captured at 209 magnification using a BX61 microscope equipped with motorized platform (Olympus, Hamburg, Germany) and digitized. Neuronal cell loss was quantified by reckoning the number of F-J-stained neurons in the full extension of CA1, CA3/CA4 pyramidal cell layers ( Figure 6A ) and in the entire amygdala. Data obtained in each of the 4 slices per brain were averaged, thus providing a single value for each brain, and this value was used for statistical analysis.
| Randomization and statistical analysis of data
Data are presented as mean AE standard error of the mean (SEM) (n = number of individual values) and are inclusive of all mice, unless otherwise indicated. Sample size was determined a priori based on previous experience with the animal model and the respective behavioral analyses and considering the principles of the 3 Rs (https://www.nc3rs. org.uk/the-3rs). Simple randomization was applied to assign a subject to a specific experimental group using a web randomization program (http://www.randomization.com). After vehicle or drug injection, mice were linked to numerical identifiers. Animal handling and data acquisition during the analyses were done by investigators blinded to the identity of the animals. Data were analyzed using a Mann-Whitney test for 2 independent groups and Kruskal-Wallis followed by Dunn or Bonferroni post hoc tests for >2 independent groups. Repeated-measures analysis of variance (ANOVA) was used to analyze the treatment effect on the number of spikes during the time of EEG monitoring using the statistical analysis system (SAS; Cary, NC, USA) MIXED procedure. The compound symmetry was chosen as the covariance structure. An interaction term between treatment and hours during SE development was introduced in the repeated-measures ANOVA. To compare the vehicle and drug-treated groups at each hour during SE we used a post hoc t test. Statistical analysis of RTqPCR data was run using ANOVA. Post hoc comparisons were adjusted for multiple hypotheses testing using the Sidak method, independently for each gene. Survival rates between Cnr1 À/À mice and their respective WT were analyzed by a log-rank test. Statistical tests were done using GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA) for Windows or R. Differences were considered statistically significant at P < .05. Figure 1A ) is a hexafluoro isopropyl (HFIP) carbamate identified from published patent literature, analogous to the previously reported SAR127303 (patent # WO11151808). To confirm selectivity, we assessed the potency of CPD-4645 against recombinant human MAGL and fatty acid amide hydrolase (FAAH). CPD-4645 is shown to be a potent MAGL inhibitor (human half maximal inhibitory concentration (IC 50 ) = 1 nmol L
À1
; Mouse IC 50 = 3.25 nmol L À1 ) and selective over FAAH (human
, 2100-fold). In addition, we profiled CPD-4645 against a panel of 13 serine hydrolases in activity-based protein profiling (ABPP) using the FP-Rhodamine probe (Fig. S1 ). CPD-4645 showed activity only toward MAGL and alpha-beta-hydrolase domain containing 6 (ABHD6) at 1 lmol L À1 concentration, which is~2509 the brain concentrations achieved in our in vivo studies.
The free-drug concentration of CPD-4645 at maximum concentration (C max ) was below the IC 50 of ABHD6 (30 vs 50 nmol L À1 ), and given the relative contribution of ABHD6 to 2-AG hydrolysis (<15%) the bulk of the pharmacodynamic effects seen with CPD-4645 were attributed to inhibition of MAGL. 26 The compound exhibits brain penetration with a half-life of 3.7 h, as assessed in the cerebellum as a surrogate area for the brain ( Figure 1B) . Because CPD-4645 has passive permeability through the blood-brain barrier (brain-to-plasma ratio >1), and given the dense vascularization of the brain, there is no expectation of region-specific brain penetration. This is supported by additional pharmacokinetic data from hemi-brain (Fig. S4 ) that show drug concentrations similar to those measured in the cerebellum. A single 10 mg/kg, sc, dose elevated brain 2-AG levels by approximately 4-fold for 8 h. Consistent with the drug's mechanism of action, we found a concomitant 4-fold decrease in levels of total arachidonic acid (AA) measured in hemi-brain ( Figure 1C) .
Liquid chromatography-mass spectrometry (LC-MS) and x-ray crystallography data with SAR127303 show covalent modification of MAGL, demonstrating the irreversibility of this chemotype.
epilepticus (SE) and cognitive deficit in standard diet (SD)-fed mice CPD-4645 blunted the development of SE in SD-fed mice. In vehicle-injected mice (n = 21), spiking activity increased in frequency during the first 2 h from KA injection (SE onset:~10 min from KA injection) reaching a plateau by 4 h, and then spike frequency progressively declined until SE spontaneously elapsed by 9 h (ie, spike frequency <1 Hz; Figure 2A , n = 21). CPD-4645 progressively reduced spike frequency (n = 21) resulting in SE abrogation by 3 h after injection versus time-matched vehicle-injected mice (P < .01) (Figure 2A,B; Fig. S2A ). PSD analysis showed that the drug reduced all high frequency (a, b, and c) bands during the first 3 h after injection, although only the reduction in the a band (8-13 Hz) was statistically significant (P < .01) (Fig. S3) .
Total duration of SE was shortened by 4 h in drug-treated mice (P < .05) versus vehicle-injected mice ( Figure 2B ). Six of 21 SE+VEHICLE and 5 of 21 mice SE+CPD-4645 died within the first 48 h after SE onset.
In the surviving mice, we determined whether CPD-4645 rescued impaired memory following SE by assessing their performance in NORT ( Figure 2C ). Naive (n = 14) and SHAM mice treated either with vehicle (n = 13) or drug (n = 8), spent more time exploring the novel object compared to the familiar one, thus indicating preference for the novel object ( Figure 2C ). SE-exposed mice in vehicle-(n = 10) and drug-treated (n = 10) groups were randomly selected for this behavioral test. SE-exposed mice injected with vehicle failed to remember the familiar object (P < .05 vs all groups), and therefore showed impaired memory ( Figure 2C ). CPD-4645 rescued this behavioral deficit in SE mice, as shown by the average discrimination index, which was similar to that in naive (n = 14) and SHAM mice (n = 8). The drug itself did not affect behavioral performance in SHAM mice ( Figure 2C 
| Effects of CPD-4645 on status epilepticus in Cnr1
À/À mice
We examined whether the mechanism of CPD-4645 inhibitory effect on SE involved the activation of CB1 receptors by elevation of 2-AG. The same treatment protocol was therefore applied to CB1 receptor-deficient (Cnr1 À/À ) mice exposed to SE and compared to Cnr1 À/À mice similarly exposed to SE but injected with vehicle ( Figure 3A-C) . CPD-4645 progressively decreased the number of spikes in Cnr1 À/À mice compared to vehicle-injected Cnr1 À/À mice, with a statistically significant effect ensuing from 3 h after administration (n = 7 each group; P < .05; Figure 3C ; Fig. S2B ). PSD analysis showed that the drug significantly reduced the a (8-13 Hz, P < .05) band during the first 3 h from injection as in WT mice ( Figure S3 ). The total duration of SE was significantly shortened by 4 h in drug-treated mice versus vehicle mice (P < .05; Figure 3B ). Cnr1 À/À mice showed a trend toward an increase in total spike number during SE compared to their corresponding wild-type mice, although this difference did not reach statistical significance (total number of spikes; WT, 40 393 AE 4708; Cnr1 À/À , 51 098 AE 4766; P = .07).
Cnr1
À/À mice exposed to SE showed a higher mortality rate compared to WT SE-exposed mice (P < .05; Figure 3D ). There was no statistically significant difference in CPD-4645 brain concentration between WT and Cnr1 À/À mice (Fig. S4 ).
| MAGL inhibition attenuates neuroinflammation
The expression of inflammatory mediators was measured by RTqPCR (Appendix S1) in the contralateral hippocampus of SE-exposed mice harvested at 1 h and 7 days after CPD-4645 or vehicle injection (the corresponding ipsilateral hippocampus was used for 2-AG measurement at 1 h while the whole ipsilateral hemisphere was used for F-J analysis of cell loss at 7 days). IL-1b (Il-1b) and COX-2 (Ptgs2) transcripts were induced by 8.4 AE 2.4-and 4.3 AE 0.8-fold, respectively, by 7 days post-SE, and this effect was reduced by CPD-4645 (P < .05; Figure 4 ). MAGL expression (Mgll) was unaltered by SE or drug treatment, which is consistent with MAGL being a constitutive (noninducible) enzyme. A different group of mice (n = 23) were fed with KD for 4 weeks and then exposed to SE. KD did not modify mice body weight in KD-fed mice (weight: 23.82 AE 0.3 g at day 1 vs 24.7 AE 0.5 g at day 28), which was similar to that of time-matched SD-fed mice (weight: 24.9 AE 0.2 g at day 1 vs 25.4 AE 0.4 g at day 28). In KD-fed mice treated with vehicle (n = 12) the temporal pattern of spikes, the spike frequency, and the total SE duration were similar to those of SD-fed mice ( Figure 5A vs Figure 2A) , except for the first hour after SE onset during which the number of spikes was significantly reduced by KD as compared to SD (SD, 5570 AE 733, n = 21; KD, 3166 AE 655, n = 12; P < .05). When CPD-4645 was injected in KD-fed mice (n = 11), SE was virtually abrogated with an immediate effect (P < .01) F I G U R E 2 Effect of CPD-4645 on status epilepticus (SE) and the associated cognitive deficit in standard diet (SD)-fed mice. A, Number of spikes during SE in mice treated with CPD-4645 (10 mg/kg, sc) or its vehicle. CPD-4645 was injected 1 and 7 h after SE onset. Data are mean AE SEM (n = 21 each group); F = 7.00, P < .01 by repeated-measures ANOVA. CPD-4645 significantly decrease the number of spikes within 2 h postinjection (*P < .05; **P < .01 by t test). B, Bar graphs (mean AE SEM) represent the average number of spikes in the first 2 h after drug or vehicle injection, and in the subsequent 3-8 h, and the effect of treatment on total SE duration. CPD-4645 abolished SE by 3 h after injection. *P < .05, **P < .01 vs SE+vehicle by Mann-Whitney test. The dotted line represents the cutoff of 3600 spikes/h (1 Hz) below which SE elapses (interspike interval >1 s). C, Discrimination index in SE-exposed mice treated with CPD-4645 (n = 10) or vehicle (n = 10) (randomly selected from mice in panel A) versus corresponding SHAM mice (implanted with electrodes, vehicle-[n = 13] or drug-injected [n = 8] but not exposed to SE). Naive mice (no surgery and no injections, n = 14) were used as additional controls. Data are mean AE SEM (n = number of mice). *P < .05 versus NAIVE and SHAM mice by Kruskal-Wallis followed by Dunn's post hoc test (Figure 5A,B; Fig. S2C ). CPD-4645 brain concentration did not significantly differ between SD-and KD-fed mice (Fig. S4 ).
| Effect of CPD-4645 on neuronal cell loss
At the end of NORT, quantitative analysis of cell loss was done in F-J-stained slices of the dorsal hippocampus ipsilateral to the injected amygdala and in the KA-injected amygdala.
In CPD-4645 treated SD-fed mice, CA1 pyramidal cell loss was reduced (P < .05) compared to vehicle-injected mice ( Figure 6A,B) , whereas a 34% decrease in cell loss was measured in CA3/CA4 (F-J cells/slice, SE+VEHICLE, 52.8 AE 10.5, n = 15; SE+CPD-4645, 34.8 AE 7.7, n = 16) although this difference did not reach statistical significance). CPD-4645 did not affect hilar cell loss assessed by counting Nissl-stained interneurons (Table S1 ). CPD-4645 reduced cell loss in the amygdala by half (P < .05; Figure 6B ).
KD itself greatly reduced the number of F-J-positive CA1 pyramidal neurons in SE-exposed mice ( Figure 6B ) but not in CA3 (not shown), hilus (Table S1 ) or amygdala ( Figure 6B ). In CPD-4645 treated KD-fed mice, virtually no cell loss was observed in CA1 ( Figure 6B ) whereas degenerating neurons were reduced similarly to vehicleinjected mice in the amygdala (P < .05; Figure 6B) . A 33% reduction (not statistically significant) was measured in CA3/4 (F-J cells/slice, SE+VEHICLE, 33.8 AE 17.0, n = 11; SE+CPD-4645, 22.8 AE 11.0, n = 10). One animal C, Bar graphs depict the effect of treatment on total SE duration and number of spikes (mean AE SEM; n = 7 each group) during the first 2 h after drug or vehicle injection and the subsequent 3-8 h. *P < .05 versus SE+vehicle by Mann-Whitney test. The dotted line represents the cutoff of 3600 spikes/h (1 Hz). D, Survival curves showing the mortality rate in Cnr1 À/À mice versus their respective WT controls exposed to SE. *P < .05 Cnr1 À/À versus WT by Kaplan-Meyer survival analysis. CPD-4645 did not affect the mortality rate in each strain in each group was omitted for poor quality of histologic preparation.
| DISCUSSION
We showed that CPD-4645, a selective inhibitor of 2-AG hydrolysis, rapidly terminates SE in mice, whereas sedative doses of diazepam were ineffective. The pharmacokinetic and pharmacodynamic profiles show rapid brain penetration and fast (within 30 min) blockade of MAGL activity, as denoted by an average 4-fold brain elevation of 2-AG with a concomitant total AA decrease. Notably, the enzyme blockade persists for up to 8 h after a single drug administration, and the compound has a similar IC 50 against the human and murine MAGL. Current standard of care for SE in humans includes benzodiazepines as first-line treatment, and if they fail then the patient is exposed to additional agents to attempt to block SE as rapidly as possible. 2 The sequelae of these treatments prolong the time spent in SE, thereby exposing the patient to an increased risk of mortality and morbidity. The fast elimination of seizures, therefore, is an urgent medical need to avoid SE evolution into refractory and superrefractory SE, and for preventing a worse prognosis. 1, 6 The rapid termination of benzodiazepine-resistant SE in mice by CPD-4645 was associated with significant improvements in pathologic outcomes, such as reduction of hippocampal and amygdalar cell loss and a rescue of recognition memory deficit. Moreover, the drug was administered 60 min after SE onset, an intervention time compatible with the proposed treatment algorithm for novel drugs for human refractory SE. In fact, there is no clear evidence to guide therapy after 40-60 min phase of unremitting SE. 2 Therefore MAGL inhibition has a potential therapeutic value for attaining rapid control of SE in humans and for improving neurologic deficits with a clinically useful therapeutic window.
In line with our findings, 2-AG, which accumulates during MAGL inhibition, was shown to inhibit seizures and delay kindling epileptogenesis by decreasing afterdischarge duration in rodents. 14, 27 These effects were attributed to a reduction of excitatory neurotransmission by 2-AG activation of CB1 receptors. MAGL inhibition may mediate therapeutic effects on SE by 2 main mechanisms: (1) accumulation of 2-AG, which in turn activates the neuronal presynaptic CB1 receptors, thereby reducing glutamate-mediated excitatory over inhibitory neurotransmission 28, 29 or acting as allosteric modulator of c-aminobutyric acid A (GABA A ) receptors 30 ;
and (2) antiinflammatory effects due to lowering of AA and eicosanoids synthesis, as well as 2-AG activation of CB2 receptors in glial cells, thereby reducing their proinflammatory phenotype. 16, 31 Our findings support that MAGL inhibition reduces SE mainly via an antiinflammatory action, since its therapeutic effect persisted in the absence of CB1 receptors. However, we observed a slight (nonstatistically significant) delay in the decrease of spiking activity at the beginning of SE in drug-treated CB1 receptors knockout mice (Figure 3A) compared to drug-treated WT mice (Figure 2A ), which may be caused by enhanced glutamate release in the absence of presynaptic inhibitory CB1 receptors. 28 This suggests that the initial therapeutic effect of CPD-4645 may initially involve 2-AG activation of neuronal CB1 receptor but it is predominantly mediated through an antiinflammatory mechanism during SE progression.
Studies in various SE models have shown a rapid and persisting neuroinflammatory response in the forebrain, originating primarily from activated microglia and astrocytes and infiltrating monocytes. This response involves the release of interleukin 1b (IL-1b) and the induction of cyclooxygenase 2 (COX-2) with concomitant production of prostaglandins (PGs). 10, 32 In particular, IL-1b-IL-IL-1 receptor type 1 (IL-1R1) and PGE2-prostaglandin EP1 receptor axes are implicated in seizure generation and recurrence, 23, 33, 34 and both IL-1b-IL-1R1 and PGE2-prostaglandin EP2 receptor activation are involved in SE-associated cell loss 10,35-37 and cognitive deficits. 37, 38 Notably, the more pronounced CPD-4645 neuroprotection in CA1 versus CA3/4 pyramidal cells is similar to the effect reported using EP2 receptor antagonists. 37 The antiseizure and neuroprotective effects of CPD-4645 may therefore be mediated by the concomitant reduction of IL-1b, AA, and COX-2, and downstream effector molecules, induced by MAGL inhibition in SE-exposed mice. In this regard, early interventions during SE with antiinflammatory drugs blocking COX-2/PGE2/EP2 receptors 10 Figure 2A ,B). The dotted line represents the cutoff of 3600 spikes/h (1 Hz). *P < .05, **P < .01 versus KD+VEHICLE by Mann-Whitney test although not affecting SE duration or severity in animal models. Moreover, the KD did not modify SE but afforded neuroprotection. Therefore, CPD-4546 effects on the pathologic sequelae may be independent of SE reduction. However, we cannot exclude that shortening of SE duration accounts for the drug's neuroprotective effects, since SE duration has an impact on the extent of cell loss. 39 The broad spectrum antiinflammatory activity attained by MAGL inhibition may represent an added value compared to drugs inhibiting specific inflammatory pathways that did not modify SE.
35-38
The immediate CPD-4546 effect on SE in KD-fed mice versus the 3 h required in SD-fed mice supports an antiinflammatory mechanism of action. Thus the high-fat, lowcarbohydrate diet characterized by ketonemia, relative hypoglycemia, and high fatty acid levels presents antiinflammatory properties. KD decreases proinflammatory cytokine levels after an immune challenge. 20 The diet's antiinflammatory effect can be mediated by dietary polyunsaturated fatty acids (PUFAs): in particular, N-3 PUFAs decrease the production of inflammatory eicosanoids, cytokines, and reactive oxygen species by inhibiting the nuclear factor kappa B (NF-jB)-mediated transcriptional activation of inflammatory genes-by activating peroxisome proliferator-activated receptors-and by promoting the generation of resolvins and docosanoids. 19, 40 Another KD-related antiinflammatory mechanism is mediated by b-hydroxybutyrate increase, which inhibits the caspase-1/inflammasome, 21 thereby reducing IL-1b secretion.
Ketone bodies, especially b-hydroxybutyrate, confer neuroprotection against different types of cellular injury 41 in line with the reduction in CA1 cell loss in KD-fed and SEexposed mice. The KD itself was unable, however, to reduce SE, except for the initial hour, suggesting that its antiinflammatory component is not sufficient for a lasting reduction of unremitting seizures, but requires an additive/ synergistic action that is provided by MAGL inhibition. Notably, KD represents an adjunctive therapeutic option for refractory SE in pediatric and adult populations, although the resolution of SE in responsive patients occurs several days after treatment initiation. 17, 18 The synergism between MAGL inhibition and KD therefore has clinical significance, representing a potential improvement over the current therapies. In summary, we provide novel evidence showing that MAGL is a promising therapeutic target to achieve a rapid termination of refractory SE and to reduce neuropathologic and neurologic downstream consequences. Our data F I G U R E 6 Effect of CPD-4645 on neuronal cell loss. A, Representative photomicrographs depicting Fluoro-Jade (F-J)-positive degenerating neurons in the hippocampus of SD-fed mice exposed to status epilepticus (SE) and treated with vehicle or CPD-4645 (10 mg/kg, sc). The schematic drawing depicts in green the hippocampal pyramidal layers where F-J cell were counted. Scale bar: 5 mm. B, Bar graphs report number of F-J-positive neurons in hippocampus and amygdala in SD-or KD-fed mice exposed to SE and treated with vehicle (n = 11-15) or CPD-4645 (n = 10-16). *P < .05 vs SE+VEHICLE by two-way ANOVA followed by Sidak's post hoc test
